BCG018 / Biocytogen - LARVOL DELTA

Preclinical efficacy of BCG018, an ADC targeting ITGB6 and incorporating a topoisomerase I inhibitor payload, was demonstrated to be effective in PDX models (AACR 2026) - "The resulting conjugate demonstrated superior efficacy to that of the benchmark ADC in PDX models, regardless of ITGB6 expression levels. Additionally, the BCG018, which is anti-ITGB6-B conjugated with a novel topoisomerase I inhibitor (BLD1102), showed superior efficacy to benchmark ADC in models of pancreatic, colorectal, and NSCLC PDX or CDX xenografts.Overall, BCG018 conjugates offer a promising strategy for targeting integrin αvβ6 in solid tumors with specific and potent efficacy."

ADC • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ITGB6